U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07813637) titled 'Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC' on Sept. 04.
Brief Summary: This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Castration-Resistant Prostate Cancer (CRPC)
Metastatic Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer Patients
Intervention:
DRUG: JANX013
JANX013 ...